Thursday, November 5, 2026

K12 Inc And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 28, 2020

K12 Inc And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. BMC Stock Holdings, Inc.

14.1% sales growth and 12.69% return on equity

BMC Stock Holdings, Inc., together with its subsidiaries, provides various building products and services for homebuilder and professional contractor customers in the United States.

BMC Stock Holdings, Inc.'s sales growth this year is expected to be 14.2% and 5% for next year.

Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 3.88B for the twelve trailing months.

BMC Stock Holdings, Inc.'s sales growth for the next quarter is 14.1%. The company's growth estimates for the ongoing quarter and the next is 86.5% and 45%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.69%.

BMC Stock Holdings, Inc.'s Stock Yearly Top and Bottom Value

BMC Stock Holdings, Inc.'s stock is valued at $55.41 at 22:22 EST, under its 52-week high of $55.48 and way above its 52-week low of $13.38.

BMC Stock Holdings, Inc.'s Moving Average

BMC Stock Holdings, Inc.'s value is way above its 50-day moving average of $47.71 and way above its 200-day moving average of $37.41.

2. K12 Inc

42.8% sales growth and 6.98% return on equity

K12 Inc., a technology-based education company, provides proprietary and third-party online curriculum, software systems, and educational services to facilitate individualized learning for students primarily in kindergarten through 12th grade (K-12) in the United States and internationally.

K12 Inc's sales growth this year is expected to be 41.9% and a negative 1.3% for next year.

Year-on-year quarterly revenue growth grew by 44.3%, now sitting on 1.15B for the twelve trailing months.

K12 Inc's sales growth for the next quarter is 42.8%. The company's growth estimates for the ongoing quarter and the next is a negative 5.8% and 40.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.98%.

K12 Inc's Stock Yearly Top and Bottom Value

K12 Inc's stock is valued at $22.83 at 22:22 EST, way below its 52-week high of $52.84 and way higher than its 52-week low of $15.06.

K12 Inc's Moving Average

K12 Inc's worth is below its 50-day moving average of $23.05 and way below its 200-day moving average of $31.49.

3. Futu Holdings Limited

149.2% sales growth and 20.42% return on equity

Futu Holdings Limited operates digitized brokerage and wealth management platform in Hong Kong, China, the United States, and internationally.

Futu Holdings Limited's sales growth this year is expected to be 170.2% and 51.5% for next year.

Year-on-year quarterly revenue growth grew by 281.7%, now sitting on N/A for the twelve trailing months.

Futu Holdings Limited's sales growth for the next quarter is 149.2%. The company's growth estimates for the present quarter and the next is 100% and negative -40%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.42%.

Futu Holdings Limited's Stock Yearly Top and Bottom Value

Futu Holdings Limited's stock is valued at $37.88 at 22:22 EST, way under its 52-week high of $51.10 and way above its 52-week low of $8.16.

Futu Holdings Limited's Moving Average

Futu Holdings Limited's value is below its 50-day moving average of $42.00 and way higher than its 200-day moving average of $32.79.

4. Vipshop Holdings Limited

45.8% sales growth and 20.62% return on equity

Vipshop Holdings Limited operates as an online discount retailer for various brands in the People's Republic of China.

Vipshop Holdings Limited's sales growth this year is expected to be 15.9% and 17.1% for next year.

Year-on-year quarterly revenue growth grew by 18.2%, now sitting on N/A for the twelve trailing months.

Vipshop Holdings Limited's sales growth for the next quarter is 45.8%. The company's growth estimates for the ongoing quarter and the next is 20% and 61.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.62%.

Vipshop Holdings Limited's Stock Yearly Top and Bottom Value

Vipshop Holdings Limited's stock is valued at $25.81 at 22:22 EST, under its 52-week high of $26.29 and way above its 52-week low of $11.53.

Vipshop Holdings Limited's Moving Average

Vipshop Holdings Limited's worth is higher than its 50-day moving average of $23.97 and way higher than its 200-day moving average of $20.33.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com